Time to grab the low hanging fruit
14/12/17 -"Genmab is down c.30% from its lifetime high levels (in March 2017) as a lower than expected sales performance for Darzalex in Q3 17 triggered a sell-off in October 2017. Moreover, the 40-50% increase ..."
Pages
49
Language
English
Published on
14/12/17
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated